STONY BROOK, N.Y., April 14, 2020 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing that enables diagnostics, pre-clinical nucleic acid-based therapeutic drug candidates, supply chain security, anti-counterfeiting and anti-theft technology, today announced its participation at Maxim Group’s Infectious Disease Virtual Conference on May 5, 2020. Applied DNA CEO Dr. James Hayward will join a panel of drug developers to share his insights on how gene-based vaccines, such as those being advanced by the Company and its joint development partner, Rome, Italy-based Takis Biotech, are at the forefront of COVID-19 vaccine development programs. The panel, entitled ‘COVID-19 (Vaccine, Treatment, Testing)’, is scheduled for 2:00 p.m. ET to 3:30 p.m. ET. To RSVP for the virtual conference, please click through: Maxim Group’s Infectious Disease Virtual Conference.
Applied DNA’s COVID-19 development program spans both vaccine candidates and a diagnostic assay kit to enable mass testing of the SARS-CoV-2, the virus that causes the disease COVID-19. Together with Takis Biotech, the Company is currently progressing five vaccine candidates that are based on COVID-19’s ‘spike’ protein. Utilizing LinearDNA™, its proprietary and patent-protected platform for large-scale DNA manufacture by PCR, the Company expects to complete production of all candidate vaccines in April 2020 and for preclinical animal testing by Takis Biotech to begin in late April 2020. Concurrently, the Company has begun manufacturing of a high-sensitivity Research Use Only (RUO) diagnostic assay kit for SARS-CoV-2 and plans to seek eventual approval under the U.S. Federal Drug Administration’s Emergency Use Authorizations.
Dr. Hayward will hold one-on-one meetings with institutional investors through Maxim Group. To schedule a one-on-one meeting, please contact email@example.com.
Applied DNA makes clear that no commercial partner has been identified to take the coronavirus vaccine candidates or diagnostic under development to market nor is there any indication that the Company’s vaccine candidates or diagnostic would be approved by regulators.
About Applied DNA Sciences
Applied DNA is a provider of molecular technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping and pre-clinical nucleic acid-based therapeutic drug candidates.
LinearDNA™ is a trademark of Applied DNA Sciences, Inc.
The Company’s common stock is listed on NASDAQ under ticker symbol ‘APDN’, and its publicly-traded warrants are listed on OTC under ticker symbol ‘APPDW’.
The statements made by Applied DNA in this press release may be “forward-looking” in nature within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe Applied DNA’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ materially from those projected due to the possibility of a failure to make timely payment on its outstanding secured convertible notes and resulting enforcement by noteholders of remedies on collateral which includes substantially all of Applied DNA’s assets, its history of net losses, limited financial resources, limited market acceptance, the fact that there has never been a commercial drug product utilizing PCR-produced DNA technology approved for therapeutic use, the uncertainties inherent in research and development, future clinical data and analysis, including whether any of Applied DNA’s or its partners product candidates will advance further in the preclinical research or clinical trial process, including receiving clearance from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies to conduct clinical trials and whether and when, if at all, they will receive final approval from the U.S. FDA or equivalent foreign regulatory agencies, the unknown outcome of any applications to U.S. FDA or equivalent regulatory agencies and various other factors detailed from time to time in Applied DNA’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 12, 2019 and our subsequent quarterly report on Form 10-Q filed on February 6, 2020, and other reports we file with the SEC, which are available at www.sec.gov. Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law.